SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999.
Life Technologies (Nasdaq: - LIFE) $50.33. Announced Monday that it is the first life science tools provider entering clinical trials to prove the safety and effectiveness of their DNA sequence-based typing (SBT) platform for analysis of the Human Leukocyte Antigen (HLA) system. Submission for 510(k) clearance of this SBT platform will follow completion of the clinical trials, which is anticipated this summer.
Life Technologies has contracted a clinical research organization to oversee the clinical trials at independent, accredited HLA typing laboratories in the United States. The laboratories will evaluate six gene regions of the HLA system using the company's Applied Biosystems 3500 Dx Genetic Analyzer, SeCore kits, and uTYPE Dx Software.
HLA typing is one of the main determinants used in patient-donor compatibility selection for individuals diagnosed with leukemia and other blood cancers, where bone marrow transplantation can be a viable treatment option. Located on chromosome six, the HLA gene family is the most variable gene in the human genome. HLA typing is the process of precisely identifying these gene variations.
What They Do: Life Technologies is a global biotechnology company dedicated to improving the human condition.
Allezoe Medical (OTCBB- ALZM) $1.39. Announced Friday afternoon that Organ Transport Systems is preparing for clinical trials of its LifeCradle and that the company plans to begin with applications of its technology to donor heart preservation. Organ Transport Systems is a wholly-owned subsidiary of Allezoe.
Organ Transport Systems' LifeCradle HR Cardiac Perfusion System is specifically designed for heart perfusion. LifeCradle HR has already undergone eight years of pre-clinical research and experience. OTS and its research collaborators have conducted numerous studies regarding the application of perfusion/preservation technologies to organs beyond the heart, including livers, kidneys, and lungs and even perfusion solutions. These studies have been done in order to define the organ-specific requirements to extend viability and even resuscitate organs that would otherwise currently be discarded.
OTS's large team of collaborators includes organ procurement organizations ("OPOs"), transplant surgeons, as well as research scientists from major academic medical centers and institutes across the nation, as well as in Australia and Europe. Through this research collaboration network, OTS has been able to better define the optimal specifications for the LifeCradle® device that will enter clinical trials for donor heart preservation.
Organ Transport Systems, through its LifeCradle, aims to directly address the discrepancy between available donor organs and those actually transplanted, by improving the preservation technology. While 27% of all donated hearts are transplanted, only 9% of lungs are, which is problematic where the average wait time for an organ can be years. This shortfall is due to the limitations of the current method of organ preservation and transport, which severely limits the time for which an organ can be preserved at high quality and, consequently, the distance it can be transported to the recipient.
What They Do: Allezoe Medical Holdings, Inc., through its subsidiary, engages in developing, patenting, and commercializing biomedical devices for human organ transplantation. It provides portable hypothermic, oxygenated preservation, and transport solutions for human organs.
ViroPharma Incorporated (Nasdaq: VPHM) $19.41. Announced Monday the launch of "HAE and Me," an online community that unites teens and adults with hereditary angioedema (HAE) through shared experiences to help them better manage their disease. The website features information about HAE, video stories, and first-hand tips from patients, as well as expert advice about living with this rare and potentially life-threatening swelling disease.
"In speaking with patients, we've learned how helpful it is for them to connect with and learn from each other, because one person's experience can inspire countless others," said Kristina Broadbelt, ViroPharma's associate director of global public relations and advocacy. "'HAE and Me' is designed to address that need by uniting and educating the HAE community and reminding patients that they're not alone."
What They Do: ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit www.SmallCapReview.com. SmallCapReview has been compensated three thousand five hundred dollars by a third party Winning Media for its efforts with regards to Allezoe Medical.
